Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court
Pharmaceutical Technology
FEBRUARY 22, 2023
Both drugs come with a high price tag. In contrast, Sanofi says that Amgen’s claims are not only invalid, but also an attempt at creating a monopoly over a particular area. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Amgen sued the two companies in 2014 over supposed patent infringement.
104 
Let's personalize your content